CAJ | 학술논문

目的:探讨孟鲁司特对支气管哮喘儿血、尿白三烯水平的影响. 方法:选取本院2012年1月~2013年6月支气管哮喘患儿162例,随机分为两组,81例患儿实施常规治疗为对照组,81例患儿在常规治疗基础上口服孟鲁司特为观察组,疗程3个月,分析两组患儿血、尿白三烯的改变情况,比较两组患儿的病症改善情况及治疗效果. 结果:两组患儿治疗后血、尿白三烯均较治疗前显著降低.观察组患儿血白三烯(5.0±1.8ng/mL)、尿白三烯(128.5±49.7ng/mL)均明显低于对照组(9.4±2.1ng/mL)、(182.9±47.6ng/mL),观察组患儿肺部湿啰音消失时间(4.7±0.9d)、咳嗽消失时间(6.7±1.1d)、住院时间(7.1±1.4d)均明显小于对照组(6.3±1.2d)、(8.2± 1.7d)、(9.7±2.0d),观察组患儿治疗总有效率(98.8%)明显高于对照组(87.7%),(P<0.05).结论:孟鲁司特可明显降低支气管哮喘患儿血、尿白三烯水平,有效改善患儿的临床病症,明显缩短治疗时间,显著提高治疗效果.
목적:탐토맹로사특대지기관효천인혈、뇨백삼희수평적영향. 방법:선취본원2012년1월~2013년6월지기관효천환인162례,수궤분위량조,81례환인실시상규치료위대조조,81례환인재상규치료기출상구복맹로사특위관찰조,료정3개월,분석량조환인혈、뇨백삼희적개변정황,비교량조환인적병증개선정황급치료효과. 결과:량조환인치료후혈、뇨백삼희균교치료전현저강저.관찰조환인혈백삼희(5.0±1.8ng/mL)、뇨백삼희(128.5±49.7ng/mL)균명현저우대조조(9.4±2.1ng/mL)、(182.9±47.6ng/mL),관찰조환인폐부습라음소실시간(4.7±0.9d)、해수소실시간(6.7±1.1d)、주원시간(7.1±1.4d)균명현소우대조조(6.3±1.2d)、(8.2± 1.7d)、(9.7±2.0d),관찰조환인치료총유효솔(98.8%)명현고우대조조(87.7%),(P<0.05).결론:맹로사특가명현강저지기관효천환인혈、뇨백삼희수평,유효개선환인적림상병증,명현축단치료시간,현저제고치료효과.
Objective:To investigate influence of montelukast on blood;urine leukotriene level in patients with bronchial asthma. Methods:162 patients with bronchial asthma were selected in hospital from January 2012 to June 2013,who were randomly divided into two groups. 81 patients treated routine treatment as control group. On basis of routine treatment, 81 patients treated montelukast as observation group.Course of treatment was 3 months. Changes of blood;urine leukotriene were analyzed in two groups.Symptoms improvement situation and treatment effect were compared between two groups. Results:Compared with before treatment , Blood; urine leukotriene after treatment decreased significantly in two groups. Blood leukotriene(5.0±1.8ng/mL)and urine leukotriene(128.5±49.7ng/mL)in observation group were significantly lower than control group (9.4±2.1ng/mL),(182.9±47.6ng/mL). Lung moist rales disappearance time (4.7±0.9d); cough disappeared time (6.7±1.1d); hospitalization time (7.1±1.4d)in observation group were significantly less than control group(6.3±1.2d),(8.2±1.7d),(9.7±2.0d). Total effective rate(98.8%)in observation group was significantly higher than control group(87.7%).(P<0.05). Conclusion:Montelukast can significantly reduce blood;urine leukotriene level in patients with bronchial asthma, which can effectively improve clinical symptoms. Montelukast can significantly shorten treatment time and improve treatment effect.